1. Signaling Pathways
  2. GPCR/G Protein
    Immunology/Inflammation
  3. CXCR

CXCR

CXC chemokine receptors; C-X-C motif chemokine receptors

CXCRs (CXC chemokine receptors) are integral membrane proteins that specifically bind and respond to cytokines of the CXC chemokine family. They represent one subfamily of chemokine receptors, a large family of G protein-linked receptors that are known as seven transmembrane (7-TM) proteins, since they span thecell membrane seven times. There are currently seven known CXC chemokine receptors in mammals, named CXCR1 through CXCR7. CXCR1 and CXCR2 are closely related receptors that recognize CXC chemokines that possess an E-L-R amino acid motif immediately adjacent to their CXC motif. CXCR3 is expressed predominantly on T lymphocytes. CXCR4 is the receptor for a chemokine known as CXCL12 (or SDF-1) and, as with CCR5, is utilized by HIV-1 to gain entry into target cells. The chemokine receptor CXCR5 is selectively expressed on B cells and is involved in lymphocyte homing and the development of normal lymphoid tissue. CXCR6 was formerly called three different names (STRL33, BONZO, and TYMSTR) before being assigned CXCR6 based on its chromosomal location and its similarity to other chemokine receptors in its gene sequence. CXCR7 was originally called RDC-1 (an orphan receptor) but has since been shown to cause chemotaxis in T lymphocytes in response to CXCL12 (the ligand for CXCR4) prompting the renaming of this molecule as CXCR7.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-125567
    Antileukinate
    Inhibitor
    Antileukinate, a hexapeptide, is a potent inhibitor of CXC-chemokine receptor (CXCR). Antileukinate inhibits neutrophil chemotaxis and activation. Antileukinate can be used for the research of acute inflammation and injury.
    Antileukinate
  • HY-161414
    trans-VUF25471
    Agonist
    trans-VUF25471 (Compound trans-3e) is a photoswitchable ACKR3 agonist. trans-VUF25471 binds and activates ACKR3 at 10-fold lower concentrations compared to its cis-isomer.
    trans-VUF25471
  • HY-RS03410
    CXCR6 Human Pre-designed siRNA Set A
    Inhibitor

    CXCR6 Human Pre-designed siRNA Set A contains three designed siRNAs for CXCR6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CXCR6 Human Pre-designed siRNA Set A
    CXCR6 Human Pre-designed siRNA Set A
  • HY-RS03402
    Cxcr2 Rat Pre-designed siRNA Set A
    Inhibitor

    Cxcr2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cxcr2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cxcr2 Rat Pre-designed siRNA Set A
    Cxcr2 Rat Pre-designed siRNA Set A
  • HY-W104862
    4-Amino-D-phenylalanine
    Inhibitor
    4-Amino-D-phenylalanine ([D-Phe(4-NH2)), a cyclic pentapeptide, inhibits CXCL12 binding to CXCR4 in FC131, with an IC50 of 0.1 μM.
    4-Amino-D-phenylalanine
  • HY-139874
    CXCR2 antagonist 3
    Antagonist
    CXCR2 antagonist 3 (compound 11h) is a potent antagonist of CXC chemokine receptor 2 (CXCR2). CXCR2 antagonist 3 demonstrates double-digit nanomolar potencies against CXCR2 and significantly inhibited neutrophil infiltration into the air pouch. CXCR2 antagonist 3 reduces the infiltration of neutrophils and MDSCs and enhance the infiltration of CD3+ T lymphocytes into the Pan02 tumor tissues.
    CXCR2 antagonist 3
  • HY-P10444
    DOTA Conjugated JM#21 derivative 7
    DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney. DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA Conjugated JM#21 derivative 7
  • HY-P1949
    Cyclic MKEY
    Cyclic MKEY is a synthetic cyclic peptide inhibitor of CXCL4-CCL5 heterodimer formation, which protects against atherosclerosis and aortic aneurysm formation by mediating inflammation. Cyclic MKEY also protects against stroke-induced brain injury in mice.
    Cyclic MKEY
  • HY-P990392
    Anti-CXCL8/IL-8 Antibody
    Anti-CXCL8/IL-8 Antibody is a human antibody expressed in CHO cells that targets CXCL8/IL-8. The Anti-CXCL8/IL-8 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CXCL8/IL-8 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-CXCL8/IL-8 Antibody
  • HY-RS03405
    Cxcr3 Rat Pre-designed siRNA Set A
    Inhibitor

    Cxcr3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cxcr3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cxcr3 Rat Pre-designed siRNA Set A
    Cxcr3 Rat Pre-designed siRNA Set A
  • HY-168971
    Paeoniflorin-6′-O-benzene sulfonate
    Antagonist
    Paeoniflorin-6′-O-benzene sulfonate (CP-25) is the inhibitor for G protein-coupled receptor kinase 2 (GRK2) that inhibits the translocation of GRK2 to the cell membrane, inhibits JAK1/STAT3 signaling pathway. Paeoniflorin-6′-O-benzene sulfonate inhibits IL-17A/CXCL2-induced proliferation of HaCaT. Paeoniflorin-6′-O-benzene sulfonate reduces the levels of inflammatory factors and chemokines such as IL-17A, IL-17F, IFN-γ, TNF-α, IL-22, IL-23, CXCL2, CXCL3 and CXCL9, alleviates Imiquimod (HY-B0180)-induced psoriasis in mouse model.
    Paeoniflorin-6′-O-benzene sulfonate
  • HY-W019787
    BAM-12P
    Activator
    BAM-12P, an endogenous opioid peptide, is a novel pro-Met-enkephalin. BAM-12P can activate human κ-opioid receptor (hKOR) with an EC50 of 101 nM and a pEC50 of 6.99. BAM-12P is a ligand for CXCR7 with an EC50 of 175 nM.
    BAM-12P
  • HY-N0011R
    Baohuoside I (Standard)
    Inhibitor
    Baohuoside I (Standard) is the analytical standard of Baohuoside I. This product is intended for research and analytical applications. Baohuoside I, a flavonoid isolated from Epimedium koreanum Nakai, acts as an inhibitor of CXCR4, downregulates CXCR4 expression, induces apoptosis and shows anti-tumor activity.
    Baohuoside I (Standard)
  • HY-RS03412
    Cxcr6 Rat Pre-designed siRNA Set A
    Inhibitor

    Cxcr6 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cxcr6 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cxcr6 Rat Pre-designed siRNA Set A
    Cxcr6 Rat Pre-designed siRNA Set A
  • HY-RS03403
    CXCR3 Human Pre-designed siRNA Set A
    Inhibitor

    CXCR3 Human Pre-designed siRNA Set A contains three designed siRNAs for CXCR3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CXCR3 Human Pre-designed siRNA Set A
    CXCR3 Human Pre-designed siRNA Set A
  • HY-146413
    HF50731
    Antagonist
    HF50731 (compound 21) is a potent CXCR4 antagonist. HF50731 shows strong CXCR4 binding affinity, with IC50 of 19.8 nM. HF50731 effectively inhibits calcium mobilization, cell migration, and HIV-1 infection via CXCR4 coreceptor, with IC50 values of 119.2 nM, 621.4 nM and 1.5 μM.
    HF50731
  • HY-P10301
    CXCL9(74-103)
    CXCL9(74-103) is a derivative peptide of CXCL9 that has a high affinity for glycosaminoglycans (GAGs) and can bind to GAGs. CXCL9(74-103) possesses anti-angiogenic properties, capable of reducing EGF, VEGF165, and FGF-2-mediated angiogenesis processes in vitro, without exhibiting cytotoxicity.
    CXCL9(74-103)
  • HY-P10333
    LIH383
    Agonist
    LIH383 is an agonist of ACKR3 (CXCR7) (EC50=0.61 nM). LIH383 efficiently induces the recruitment of β-arrestin to ACKR3 but does not trigger typical G protein signaling.
    LIH383
  • HY-P4109
    vMIP-II (1-21)
    Inhibitor
    vMIP-II (1-21) (NT21MP) is an inhibitor of CXCR4. vMIP-II (1-21) interacts broadly with CC and CXC chemokine receptors. vMIP-II (1-21) inhibits CXCR4 by competing with 125I-SDF-1R for binding sites (IC50=190 nM).
    vMIP-II  (1-21)
  • HY-P10321
    HBP08
    HBP08 is a selective inhibitor of CXCL12/HMGB1 interaction. HBP08 has a high affinity for HMGB1 (Kd=0.8 μM). HBP08 inhibits CXCL12-mediated cell migration.
    HBP08
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.